Ruishun Biotechnology

China
Shimenjie, Jiangxi, China

Company profile

Ruishun Biotechnology company profile

Ruishun Biotechnology was established in February 2012, focusing on the development of off-the-shelf universal DNT immune cells. A complete cell production, preparation, and quality control system has been established, and the pipeline for relapsed and refractory acute myeloid leukemia has entered clinical phase I, making it the world's first non-gene editing general-purpose tumor immune cell product . The company will further expand the indication scope of DNT cells on the basis of continuous optimization of the existing process, so as to solve the unmet clinical needs with better efficacy.

Business identity

Operating status
Active
Company type
For Profit
Founded
2012-02-01, Month

Headquarters

Country code
CN
Continent
Asia

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
2
Total equity funding
$8.7M
Last funding
Series A / $8.7M / 2022-08-17
Last equity funding
Series A / $8.7M
Investors
2
Lead investors
1

Founders and investors

Lead investors

Baidu Ventures

Investors

Baidu VenturesHuaxia Heng Tian